All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Bookmark this article
The MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, What are the highlights of the ESH 8th Translational Research Conference: Myelodysplastic Syndromes?
Highlights of the 8th Translational Research Conference: Myelodysplastic Syndromes
De Witte begins by discussing new molecular MDS-specific mutations and how they can impact diagnosis and prognosis. De Witte goes on to define the pre-stages of MDS and myeloproliferative neoplasms (MPN), in particular clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenia of undetermined significance (CCUS).
CCUS with dysplasia: A clinically relevant precursor to MDS
Clonal hematopoiesis of indeterminate potential (CHIP) evolves into hematologic cancers at a much slower rate compared to clonal cytopenia of undetermined significance (CCUS). CCUS therefore...
Editorial theme | Genetic pathogenesis of MDS: Translating molecular advances into better diagnosis and prognosis of CCUS and MDS
The last 30 years of advances in molecular biology and high-throughput techniques have significantly impacted the...
Subscribe to get the best content related to MDS delivered to your inbox